• Proof of concept complete with over eight studies demonstrating fertility control in wildlife field trials
• Clear development pathway
• EPA approval expected by 1Q 2020
• Revenue can be generated quickly
• Positive ROI and ROE 
• Commercial-ready in one year from closing on funding means cashflow can fund life-cycle management and portfolio expansion to develop vaccines for other species without need for additional dilutive funding
• For information on investing contact us

• Immunocontraception has immediate application in control of overabundant wild horse populations and urban deer. 
• Feral Cats
• Feral Dogs
• Macaques
• Wild Burros
• Feral Cattle
• Feral Camels
• Feral Hogs

USE OF PROCEEDS:

• Create, standardize and validate manufacturing protocol 
• Compile submission dossier for EPA
• QA:Manufacture batches to affirm antibody response and release specs
• Field testing of SpayVac immunocontraception with potential customers
• Vaccination of additional overabundant species to expand usage to a greater number of species
• Develop other immunocontraceptive vaccines for feral cats and feral dogs
• Set up long-term production facility